RICH1 is a novel key suppressor of isoproterenol‑ or angiotensin II‑induced cardiomyocyte hypertrophy

Wang,Siqi; Wang,Xin; Ling,Li; Li,Cairong; Ren,Zhanhong

doi:10.3892/mmr.2024.13193

RICH1 is a novel key suppressor of isoproterenol‑ or angiotensin II‑induced cardiomyocyte hypertrophy

Authors:
- Siqi Wang
- Xin Wang
- Li Ling
- Cairong Li
- Zhanhong Ren
View Affiliations

Affiliations: School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, School of Mathematics and Statistics, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, School of Clinical Medicine, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Hubei Key Laboratory of Diabetes and Angiopathy, Medicine Research Institute, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China
Published online on: March 4, 2024 https://doi.org/10.3892/mmr.2024.13193
Article Number: 69
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiac hypertrophy is one of the key processes in the development of heart failure. Notably, small GTPases and GTPase‑activating proteins (GAPs) serve essential roles in cardiac hypertrophy. RhoGAP interacting with CIP4 homologs protein 1 (RICH1) is a RhoGAP that can regulate Cdc42/Rac1 and F‑actin dynamics. RICH1 is involved in cell proliferation and adhesion; however, to the best of our knowledge, its role in cardiac hypertrophy remains unknown. In the present study, the role of RICH1 in cardiomyocyte hypertrophy was assessed. Cell viability was analyzed using the Cell Counting Kit‑8 assay and cells surface area (CSA) was determined by cell fluorescence staining. Reverse transcription‑quantitative PCR and western blotting were used to assess the mRNA expression levels of hypertrophic marker genes, such as Nppa, Nppb and Myh7, and the protein expression levels of RICH1, respectively. RICH1 was shown to be downregulated in isoproterenol (ISO)‑ or angiotensin II (Ang II)‑treated H9c2 cells. Notably, overexpression of RICH1 attenuated the upregulation of hypertrophy‑related markers, such as Nppa, Nppb and Myh7, and the enlargement of CSA induced by ISO and Ang II. By contrast, the knockdown of RICH1 exacerbated these effects. These findings suggested that RICH1 may be a novel suppressor of ISO‑ or Ang II‑induced cardiomyocyte hypertrophy. The results of the present study will be beneficial to further studies assessing the role of RICH1 and its downstream molecules in inhibiting cardiac hypertrophy.

View Figures

View References

1	Bernardo BC, Weeks KL, Pretorius L and McMullen JR: Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol Ther. 128:191–227. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ritterhoff J and Tian R: Metabolic mechanisms in physiological and pathological cardiac hypertrophy: New paradigms and challenges. Nat Rev Cardiol. 20:812–829. 2023. View Article : Google Scholar : PubMed/NCBI
3	Zeidan A, Javadov S and Karmazyn M: Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes. Cardiovasc Res. 72:101–111. 2006. View Article : Google Scholar : PubMed/NCBI
4	Rangrez AY, Bernt A, Poyanmehr R, Harazin V, Boomgaarden I, Kuhn C, Rohrbeck A, Frank D and Frey N: Dysbindin is a potent inducer of RhoA-SRF-mediated cardiomyocyte hypertrophy. J Cell Biol. 203:643–656. 2013. View Article : Google Scholar : PubMed/NCBI
5	Wu G, Yussman MG, Barrett TJ, Hahn HS, Osinska H, Hilliard GM, Wang X, Toyokawa T, Yatani A, Lynch RA, et al: Increased myocardial Rab GTPase expression: A consequence and cause of cardiomyopathy. Circ Res. 89:1130–1137. 2001. View Article : Google Scholar : PubMed/NCBI
6	Ramos-Kuri M, Meka SH, Salamanca-Buentello F, Hajjar RJ, Lipskaia L and Chemaly ER: Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies. Biol Res. 54:232021. View Article : Google Scholar : PubMed/NCBI
7	Tcherkezian J and Lamarche-Vane N: Current knowledge of the large RhoGAP family of proteins. Biol Cell. 99:67–86. 2007. View Article : Google Scholar : PubMed/NCBI
8	Johnson DS and Chen YH: Ras family of small GTPases in immunity and inflammation. Curr Opin Pharmacol. 12:458–463. 2012. View Article : Google Scholar : PubMed/NCBI
9	Reiner DJ and Lundquist EA: Small GTPases. WormBook. 2018:1–65. 2018. View Article : Google Scholar : PubMed/NCBI
10	Song S, Cong W, Zhou S, Shi Y, Dai W, Zhang H, Wang X, He B and Zhang Q: Small GTPases: Structure, biological function and its interaction with nanoparticles. Asian J Pharm Sci. 14:30–39. 2019. View Article : Google Scholar : PubMed/NCBI
11	Aikawa R, Komuro I, Nagai R and Yazaki Y: Rho plays an important role in angiotensin II-induced hypertrophic responses in cardiac myocytes. Mol Cell Biochem. 212:177–182. 2000. View Article : Google Scholar : PubMed/NCBI
12	Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Zhu W, Kadowaki T and Yazaki Y: Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res. 84:458–466. 1999. View Article : Google Scholar : PubMed/NCBI
13	Schmidt A and Hall A: Guanine nucleotide exchange factors for Rho GTPases: Turning on the switch. Genes Dev. 16:1587–1609. 2002. View Article : Google Scholar : PubMed/NCBI
14	Cherfils J and Zeghouf M: Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol Rev. 93:269–309. 2013. View Article : Google Scholar : PubMed/NCBI
15	Barbeau PA, Houad JM, Huber JS, Paglialunga S, Snook LA, Herbst EAF, Dennis KMJH, Simpson JA and Holloway GP: Ablating the Rab-GTPase activating protein TBC1D1 predisposes rats to high-fat diet-induced cardiomyopathy. J Physiol. 598:683–697. 2020. View Article : Google Scholar : PubMed/NCBI
16	Binsch C, Barbosa DM, Hansen-Dille G, Hubert M, Hodge SM, Kolasa M, Jeruschke K, Weiß J, Springer C, Gorressen S, et al: Deletion of Tbc1d4/As160 abrogates cardiac glucose uptake and increases myocardial damage after ischemia/reperfusion. Cardiovasc Diabetol. 22:172023. View Article : Google Scholar : PubMed/NCBI
17	Bisserier M, Berthouze-Duquesnes M, Breckler MS, Tortosa F, Fazal L, de Régibus A, Laurent AC, Varin A, Lucas A, Branchereau M, et al: Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling. Circulation. 131:390–400. 2015. View Article : Google Scholar : PubMed/NCBI
18	De Windt LJ, Lim HW, Bueno OF, Liang Q, Delling U, Braz JC, Glascock BJ, Kimball TF, del Monte F, Hajjar RJ and Molkentin JD: Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 98:3322–3327. 2001. View Article : Google Scholar : PubMed/NCBI
19	Xu J, Ismat FA, Wang T, Lu MM, Antonucci N and Epstein JA: Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res. 105:304–311. 2009. View Article : Google Scholar : PubMed/NCBI
20	Richnau N, Fransson A, Farsad K and Aspenström P: RICH-1 has a BIN/Amphiphysin/Rvsp domain responsible for binding to membrane lipids and tubulation of liposomes. Biochem Biophys Res Commun. 320:1034–1042. 2004. View Article : Google Scholar : PubMed/NCBI
21	Wells CD, Fawcett JP, Traweger A, Yamanaka Y, Goudreault M, Elder K, Kulkarni S, Gish G, Virag C, Lim C, et al: A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell. 125:535–548. 2006. View Article : Google Scholar : PubMed/NCBI
22	Nagy Z, Wynne K, von Kriegsheim A, Gambaryan S and Smolenski A: Cyclic nucleotide-dependent protein kinases target ARHGAP17 and ARHGEF6 complexes in platelets. J Biol Chem. 290:29974–29983. 2015. View Article : Google Scholar : PubMed/NCBI
23	Richnau N and Aspenström P: Rich, a rho GTPase-activating protein domain-containing protein involved in signaling by Cdc42 and Rac1. J Biol Chem. 276:35060–35070. 2001. View Article : Google Scholar : PubMed/NCBI
24	Pan SL, Deng YY, Fu J, Zhang YH, Zhang ZJ and Qin XJ: ARHGAP17 enhances 5-Fluorouracil-induced apoptosis in colon cancer cells by suppressing Rac1. Neoplasma. 69:640–647. 2022. View Article : Google Scholar : PubMed/NCBI
25	Wang L, Yang X, Wan L, Wang S, Pan J and Liu Y: ARHGAP17 inhibits pathological cyclic strain-induced apoptosis in human periodontal ligament fibroblasts via Rac1/Cdc42. Clin Exp Pharmacol Physiol. 47:1591–1599. 2020. View Article : Google Scholar : PubMed/NCBI
26	Wu PR, Chiang SY, Midence R, Kao WC, Lai CL, Cheng IC, Chou SJ, Chen CC, Huang CY and Chen RH: Wdr4 promotes cerebellar development and locomotion through Arhgap17-mediated Rac1 activation. Cell Death Dis. 14:522023. View Article : Google Scholar : PubMed/NCBI
27	Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N, Persson NL, Shimono A, Speicher DW, Marmorstein R, et al: A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell. 19:527–540. 2011. View Article : Google Scholar : PubMed/NCBI
28	Ullah R, Yin Q, Snell AH and Wan L: RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 85:123–154. 2022. View Article : Google Scholar : PubMed/NCBI
29	Tian Q, Gao H, Zhou Y, Zhu L and Yang J, Wang B, Liu P and Yang J: RICH1 inhibits breast cancer stem cell traits through activating kinases cascade of Hippo signaling by competing with Merlin for binding to Amot-p80. Cell Death Dis. 13:712022. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Aslan JE: Platelet Rho GTPase regulation in physiology and disease. Platelets. 30:17–22. 2019. View Article : Google Scholar : PubMed/NCBI
32	Zhang J, Wang J, Zhou YF, Ren XY, Lin MM, Zhang QQ, Wang YH and Li X: Rich1 negatively regulates the epithelial cell cycle, proliferation and adhesion by CDC42/RAC1-PAK1-Erk1/2 pathway. Cell Signal. 27:1703–1712. 2015. View Article : Google Scholar : PubMed/NCBI
33	Luan Y, Luan Y, Feng Q, Chen X, Ren KD and Yang Y: Emerging role of mitophagy in the heart: Therapeutic potentials to modulate mitophagy in cardiac diseases. Oxid Med Cell Longev. 2021:32599632021. View Article : Google Scholar : PubMed/NCBI
34	Pan C, Wang S, Liu C and Ren Z: Actin-binding proteins in cardiac hypertrophy. Cells. 11:35662022. View Article : Google Scholar : PubMed/NCBI
35	Yan ZP, Li JT, Zeng N and Ni GX: Role of extracellular signal-regulated kinase 1/2 signaling underlying cardiac hypertrophy. Cardiol J. 28:473–482. 2021. View Article : Google Scholar : PubMed/NCBI
36	Zoppino FC, Militello RD, Slavin I, Alvarez C and Colombo MI: Autophagosome formation depends on the small GTPase Rab1 and functional ER exit sites. Traffic. 11:1246–1261. 2010. View Article : Google Scholar : PubMed/NCBI
37	Sun Y, Xu C, Jiang Z and Jiang X: DEF6(differentially exprehomolog. exacerbates pathological cardiac hypertrophy via RAC1. Cell Death Dis. 14:4832023. View Article : Google Scholar : PubMed/NCBI
38	Li G, Wang Y, Guo XB and Zhao B: CDC42 regulates cell proliferation and apoptosis in bladder cancer via the IQGAP3-mediated Ras/ERK pathway. Biochem Genet. 60:2383–2398. 2022. View Article : Google Scholar : PubMed/NCBI
39	Mondaca-Ruff D, Araos P, Yañez CE, Novoa UF, Mora IG, Ocaranza MP and Jalil JE: Hydrochlorothiazide reduces cardiac hypertrophy, fibrosis and rho-kinase activation in DOCA-salt induced hypertension. J Cardiovasc Pharmacol Ther. 26:724–735. 2021. View Article : Google Scholar : PubMed/NCBI
40	Moradi A, Maroofi A, Hemati M, Hashemzade T, Alborzi N and Safari F: Inhibition of GTPase Rac1 expression by vitamin D mitigates pressure overload-induced cardiac hypertrophy. Int J Cardiol Heart Vasc. 37:1009222021.PubMed/NCBI
41	Liao JK: Statin therapy for cardiac hypertrophy and heart failure. J Investig Med. 52:248–253. 2004. View Article : Google Scholar : PubMed/NCBI